These recombinant molecules compete with membrane-bound ACE2 for SARS-CoV-2 binding, leaving ACE2 on endothelial cell surfaces unoccupied and able to convert angiotensin II to angiotensin (1–7), thus moderating the excessive inflammatory response seen in COVID-19 [243]. The gene discussed is ACE2; the disease is COVID-19.